The Astellas Way Blog

Gratitude for the People Behind a New Therapy in the Fight Against Cancer

By Percival Barretto-Ko, President, Astellas Americas

Nov 29, 2018

The U.S. Food and Drug Administration’s approval of XOSPATA® (gilteritinib) is a proud moment for Astellas. This approval is about more than pride, though — it’s about gratitude. When products that stand to make a difference in patients’ lives come to the market, it’s important to remember the faces behind the achievement. And so, today, I want to say thank you.

When I think about gratitude, I think about patients who chose to be part of our clinical trials in the face of a devastating diagnosis. Facing their own mortality, they chose to help others, which takes an enormous amount of courage and selflessness. I am grateful for the choice that every patient made to participate in the XOSPATA clinical trials that brought us here today. I am also thankful for the caregivers who supported their loved ones’ participation in our trials.

In addition to patients and to caregivers, I’m grateful to the regulators who understood the desperate need of those suffering. I’m also thankful for the physicians who guided XOSPATA’s clinical development, the medical community advocates who recognized the unmet medical need, and finally, the researchers who strove tirelessly in the lab to advance science.

To all of those who participated in XOSPATA’s clinical trials and approval, thank you.

At Astellas, we are focused on “changing tomorrow” for patients suffering from diseases. And today, together, we have given new hope to patients and taken an important step towards accomplishing our goal.